Anti-LMAN2L/VIPL antibody (bs-18307R)

Anti-LMAN2L/VIPL antibody

DATASHEET

Host:Rabbit

Target Protein:LMAN2L/VIPL

IR:Immunogen Range:45-140/348

Clonality:Polyclonal

Isotype:IgG

Entrez Gene:81562

Swiss Prot:Q9H0V9

Source:KLH conjugated synthetic peptide derived from human LMAN2L/VIPL:45-140/348 

Purification:affinity purified by Protein A

Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Background:Lectin mannose-binding 1, also designated vesicular integral-membrane protein (VIP36), and lectin mannose-binding 2, also designated ERGIC-53, comprise a family of membrane bound, ubiquitously expressed proteins involved in the selective transport of newly synthesized glycoproteins from the endoplasmic reticulum to the ER-Golgi intermediate compartment. VIPL (VIP36-like protein), also known as LMAN2L (lectin, mannose-binding 2-like), is a 348 amino acid single-pass type I membrane protein that localizes to the endoplasmic reticulum and Golgi apparatus. Containing one L-type lectin-like domain, VIPL is highly expressed in skeletal muscle and kidney, and is found at intermediate levels in heart, liver and placenta, and low levels in brain, thymus, spleen, small intestine and lung. VIPL is suggested to be involved in the regulation of export from the endoplasmic reticulum of a subset of glycoproteins. VIPL may function as a regulator of ERGIC-53. VIPL exists a two alternatively spliced isoforms.

Size:100ul

Concentration:1mg/ml

Applications:WB(1:500-2000)
ELISA(1:5000-10000)
IHC-P(1:100-500)
IHC-F(1:100-500)
ICC(1:100-500)
IF(1:100-500)

Cross Reactive Species:Human
Mouse
Rat
Dog
Pig
Cow
Horse
Rabbit
Sheep
.

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Sample: Muscle (Mouse) Lysate at 40 ug
Primary: Anti-LMAN2L/VIPL (bs-18307R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 38 kD
Observed band size: 38 kD